TABLE 3.
Bilitec 2000 24 h bile acid monitoring pre- and post-treatment
| Bile reflux |
Group A (observation) |
Group B (rabeprazole) |
Group C (hydrotalcite) |
Group D (combination) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre | Post | P | Pre | Post | P | Pre | Post | P | Pre | Post | P | |
| Reflux episodes | 69.04±23.00 | 63.46±21.34 | 0.091 | 68.64±22.70 | 62.68±22.40 | 0.060 | 67.64±21.59 | 63.04±21.88 | 0.059 | 68.38±22.12 | 53.85±19.40 | 0.039* |
| Reflux episodes >5 min | 17.89±1.78 | 18.02±1.63 | 0.068 | 19.37±2.70 | 17.97±1.30 | 0.085 | 18.40±2.70 | 15.20±2.51 | 0.100 | 18.26±1.80 | 9.70±1.20 | 0.037* |
| Total percent time ABS >0.14 units | 49.67±21.45 | 46.76±19.00 | 0.089 | 48.64±23.10 | 38.12±13.80 | 0.032* | 47.18±16.79 | 36.87±12.90 | 0.047* | 48.02±11.93 | 33.60±8.80 | 0.042*† |
Pre- and post-treatment data presented as mean ± SD.
*
P<0.05 compared pre- and post-treatment in each group;
†
P<0.05 compared among the four groups. ABS Absorbance. Bilitec 2000, Medtronic Synetics, Sweden